Bristol Myers, 2seventy bio receive FDA approval for Abecma to treat multiple myeloma
Bristol Myers Squibb (NYSE:BMY) stated on Friday that the corporate and 2seventy bio (NASDAQ:TSVT) obtained U.S. FDA approval for Abecma within the remedy of grownup sufferers with relapsed or refractory ...